For seed & Series A investors
Short notes on what usually breaks in complex packages when the deck looks fine and the science bench is thin. Pair with prior work for anonymized modality accounts and method for how a Decision Sprint runs.
10 notes · written for live deal deadlines
Common claim patterns by modality class.
Decision problem. What must be true about vesicle identity and controls before mechanism claims can carry a check?
EV and exosome theses often lead with biology language. Under a live deal deadline, identity, purity, and potency definitions decide whether the package is investable.
Decision problem. Is the next round buying a clinical claim, or an unresolved potency and comparability project?
Autologous and allogeneic packages often mix platform promise with thin release logic. The raise should buy a claim-resolving path — not an unowned manufacturing thesis.
Decision problem. Is the check buying a product path in the intended tissue, or unresolved delivery science?
ASO, siRNA, and related nucleic-acid theses frequently sell platform chemistry while the investable question is tissue exposure, durability, and off-target bounds.
Decision problem. When an oral incretin thesis sells convenience, what exposure constraint still kills the financing story?
For oral metabolic assets, fed/fasted exposure reliability is often the hidden claim behind adherence narratives.
Decision problem. Does target biology plus format novelty survive developability and competitor read-through before the raise?
mAb and related biologic packages can look target-rich while epitope rationale, crowding, and manufacturability remain financing-material risks.
Decision problem. Do analytical claims, intended use, and path-to-adoption cohere under the stated clock?
Sensitivity and specificity matter — and so do intended use, workflow fit, and whether CLIA/LDT/FDA framing matches the commercial timeline.
Decision problem. Which claims stay inside a lighter regulatory path — and which processing moves reclassify risk?
HCTP packages can look lightly regulated until processing or intended-use drift quietly implies a heavier path and capital need.
How to structure a science review on a short clock.
Decision problem. Is this raise underwriting a product path or an unresolved platform science project?
Many decks sell a platform and ask for an asset-sized decision. The memo should say which claim the capital actually buys.
Decision problem. How should a lean team test science under a short deal deadline?
A fixed-scope sprint cannot cover every domain. Mapping the claims that must hold keeps the memo usable.
When an outside science review is worth buying—and when it is not.
Decision problem. When does an outsourced science review create no decision value?
Anti-ICP clarity protects both sides. Some requests should be declined in the first call.
Scope a Decision Sprint for one $1–10M opportunity under your deal deadline.